Common use of Patent Listings Clause in Contracts

Patent Listings. AbbVie shall have the sole right to make, and shall exercise Commercially Reasonable Efforts with respect to making, all filings with Regulatory Authorities in the Territory with respect to Receptos Patents and AbbVie Patents, including as required or allowed (i) in the United States, in the FDA’s Orange Book, and (ii) outside the United States, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents. In this regard, AbbVie shall make such decisions without regard for any compounds, technologies or other intellectual property beyond Licensed Compounds and Licensed Products if it is reasonable to expect that the potential protection of any Licensed Compound or Licensed Product could be adversely affected by taking any such other interests into account. Receptos shall (A) provide to AbbVie all Information, including a correct and complete list of Receptos Patents covering any Licensed Product or otherwise necessary or reasonably useful to enable AbbVie to make such filings with Regulatory Authorities in the Territory with respect to such Patents, and (B) cooperate with AbbVie’s reasonable requests in connection therewith, including meeting any submission deadlines, in each case ((A) and (B)), to the extent required or permitted by Applicable Law.

Patent Listings. AbbVie shall have the sole right to make, and shall exercise Commercially Reasonable Efforts with respect to making, make all filings with Regulatory Authorities in the AbbVie Territory with respect to Receptos Galapagos Patents, AbbVie Patents and AbbVie Joint Patents, including as required or allowed (i) in the United States, in the FDA’s Orange Book, and (ii) outside the United States, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents. In this regard, AbbVie shall make such decisions without regard for any compounds, technologies or other intellectual property beyond Licensed Compounds and Licensed Products if it is reasonable to expect that the potential protection of any Licensed Compound or Licensed Product could be adversely affected by taking any such other interests into account. Receptos Galapagos shall (Aa) provide to AbbVie all Information, including a correct and complete list of Receptos Galapagos Patents covering any Licensed Product Product, or otherwise necessary or reasonably useful useful, to enable AbbVie to make such filings with Regulatory Authorities in the Territory with respect to such Patents, and (Bb) cooperate with AbbVie’s reasonable requests in connection therewiththerewith or with any Joint Patents, including meeting any submission deadlines, in each case ((Aa) and (Bb)), to the extent required or permitted by Applicable Law.. All filings with Regulatory Authorities in the Galapagos Territory with respect to Galapagos Patents, AbbVie Patents and Joint Patents shall be subject to the review and approval of AbbVie. ***Confidential Treatment Requested***

Patent Listings. AbbVie shall have the sole right to make, and shall exercise Commercially Reasonable Efforts with respect to making, make all filings with Regulatory Authorities in the AbbVie Territory with respect to Receptos Galapagos Patents, AbbVie Patents and AbbVie Joint Patents, including as required or allowed (i) in the United States, in the FDA’s Orange Book, and (ii) outside the United States, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents. In this regard, AbbVie shall make such decisions without regard for any compounds, technologies or other intellectual property beyond Licensed Compounds and Licensed Products if it is reasonable to expect that the potential protection of any Licensed Compound or Licensed Product could be adversely affected by taking any such other interests into account. Receptos Galapagos shall (Aa) provide to AbbVie all Information, including a correct and complete list of Receptos Galapagos Patents covering any Licensed Product Product, or otherwise necessary or reasonably useful useful, to enable AbbVie to make such filings with Regulatory Authorities in the Territory with respect to such Patents, and (Bb) cooperate with AbbVie’s reasonable requests in connection therewiththerewith or with any Joint Patents, including meeting any submission deadlines, in each case ((Aa) and (Bb)), to the extent required or permitted by Applicable Law. All filings with Regulatory Authorities in the Galapagos Territory with respect to Galapagos Patents, AbbVie Patents and Joint Patents shall be subject to the review and approval of AbbVie.